FR23C1005I1 - Vaccins contre les flavivirus - Google Patents
Vaccins contre les flavivirusInfo
- Publication number
- FR23C1005I1 FR23C1005I1 FR23C1005C FR23C1005C FR23C1005I1 FR 23C1005 I1 FR23C1005 I1 FR 23C1005I1 FR 23C1005 C FR23C1005 C FR 23C1005C FR 23C1005 C FR23C1005 C FR 23C1005C FR 23C1005 I1 FR23C1005 I1 FR 23C1005I1
- Authority
- FR
- France
- Prior art keywords
- vaccines against
- against flavivirus
- flavivirus
- vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34894902P | 2002-01-15 | 2002-01-15 | |
US38528102P | 2002-05-31 | 2002-05-31 | |
EP03748884A EP1471873A4 (fr) | 2002-01-15 | 2003-01-15 | Vaccins contre les flavivirus |
PCT/US2003/001214 WO2003103571A2 (fr) | 2002-01-15 | 2003-01-15 | Vaccins contre les flavivirus |
EP10013094A EP2295023A1 (fr) | 2002-01-15 | 2003-01-15 | Vaccins contre les flavivirus |
Publications (1)
Publication Number | Publication Date |
---|---|
FR23C1005I1 true FR23C1005I1 (fr) | 2023-03-24 |
Family
ID=29739394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR23C1005C Active FR23C1005I1 (fr) | 2002-01-15 | 2023-01-12 | Vaccins contre les flavivirus |
Country Status (14)
Country | Link |
---|---|
US (5) | US7459160B2 (fr) |
EP (3) | EP1471873A4 (fr) |
JP (2) | JP2005519639A (fr) |
KR (2) | KR101074175B1 (fr) |
CN (1) | CN103555669B (fr) |
AU (1) | AU2003267937C1 (fr) |
BR (3) | BR122018075729B8 (fr) |
CA (1) | CA2473321C (fr) |
ES (1) | ES2924640T3 (fr) |
FR (1) | FR23C1005I1 (fr) |
IL (3) | IL163001A (fr) |
MX (1) | MXPA04006870A (fr) |
NZ (1) | NZ534159A (fr) |
WO (1) | WO2003103571A2 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
CN1551782A (zh) | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
EP1471873A4 (fr) | 2002-01-15 | 2005-03-16 | Acambis Inc | Vaccins contre les flavivirus |
US20050002968A1 (en) * | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
DE60330708D1 (de) | 2002-11-15 | 2010-02-04 | Sanofi Pasteur Biologics Co | Impfstoff gegen das west-nile-virus |
US7482017B2 (en) | 2004-09-09 | 2009-01-27 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
EA015907B1 (ru) * | 2004-10-20 | 2011-12-30 | Санофи Пастер Байолоджикс Ко. | Рекомбинантный флавивирус и его применение |
AU2013204985B2 (en) * | 2005-04-24 | 2016-01-28 | Sanofi Pasteur Biologics, Llc | Recombinant flavivirus vaccines |
BRPI0609949A2 (pt) | 2005-04-24 | 2010-05-11 | Acambis Inc | flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
RU2541784C2 (ru) | 2006-11-07 | 2015-02-20 | Санофи Пастер Байолоджикс Ко. | Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения |
EP2589392B1 (fr) | 2008-03-05 | 2016-11-30 | Sanofi Pasteur | Procédé de stabilisation d'une composition vaccinale contenant un adjuvant |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
US10081795B2 (en) * | 2010-03-24 | 2018-09-25 | Research Development Foundation | Flavivirus host range mutations and uses thereof |
WO2012003320A2 (fr) | 2010-07-01 | 2012-01-05 | Research Development Foundation | Mutations de gamme d'hôtes de flavivirus et leurs utilisations |
SG11201500412TA (en) * | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions |
BR112015031226A2 (pt) | 2013-06-21 | 2017-08-29 | Merck Sharp & Dohme | Composição de vacina, e, uso da composição de vacina |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
US10449243B2 (en) | 2014-12-22 | 2019-10-22 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
EP3316905A1 (fr) | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Vaccination simultanée contre la dengue et la fièvre jaune |
US20180229407A1 (en) * | 2017-02-03 | 2018-08-16 | Marhaygue, Llc | Structural Composition and Method |
WO2019069130A1 (fr) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | Compositions pour vaccination de rappel contre la dengue |
CN111556896A (zh) | 2017-12-21 | 2020-08-18 | 株式会社绿色生物医药 | 交叉免疫抗原疫苗及其制备方法 |
KR102269663B1 (ko) | 2018-04-27 | 2021-06-28 | 주식회사 레모넥스 | 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물 |
AU2021364852A1 (en) * | 2020-10-23 | 2023-06-22 | Sk Bioscience Co., Ltd. | Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen |
WO2023204693A1 (fr) * | 2022-04-22 | 2023-10-26 | 에스케이바이오사이언스 주식회사 | Composition pour réduire la taille ou le volume d'un tissu cible ou kit la comprenant |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
ES2153223T3 (es) | 1991-09-19 | 2001-02-16 | Us Health | Flavivirus quimericos y/o flavivirus de crecimiento restringido. |
US6136561A (en) * | 1995-05-24 | 2000-10-24 | Hawaii Biotechnology Group, Inc. | Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems |
US6171864B1 (en) * | 1996-07-05 | 2001-01-09 | Pioneer Hi-Bred International, Inc. | Calreticulin genes and promoter regions and uses thereof |
DE69841690D1 (de) * | 1997-02-28 | 2010-07-08 | Acambis Inc | Chimäre Impfstoffe gegen Flaviviren |
US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BRPI9701774B8 (pt) * | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
US6416763B1 (en) * | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
WO2001039802A1 (fr) * | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Vaccins de flavivirus chimere |
DK2295968T3 (da) * | 1999-12-03 | 2012-12-17 | Baxter Healthcare Sa | Pyrogenicitetsprøve til anvendelse i forbindelse med automatiserede immunanalysesystemer |
AU3844101A (en) | 2000-02-16 | 2001-08-27 | Us Health | Avirulent, immunogenic flavivirus chimeras |
GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
CN1551782A (zh) * | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
US6682883B1 (en) * | 2001-07-19 | 2004-01-27 | Acambis, Inc. | Diagnosis of flavivirus infection |
RU2313367C2 (ru) | 2001-10-19 | 2007-12-27 | Экэмбис, Инк. | Способы профилактики и лечения инфекции, вызываемой флавивирусами у животных |
EP1471873A4 (fr) | 2002-01-15 | 2005-03-16 | Acambis Inc | Vaccins contre les flavivirus |
US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
DE60330708D1 (de) * | 2002-11-15 | 2010-02-04 | Sanofi Pasteur Biologics Co | Impfstoff gegen das west-nile-virus |
US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
WO2005040390A1 (fr) | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | Vaccin recombine utilisant le virus de la fievre jaune comme vecteur |
WO2005049815A1 (fr) | 2003-11-21 | 2005-06-02 | K.U.Leuven Research & Development | Replication de flavivirus |
EA015907B1 (ru) | 2004-10-20 | 2011-12-30 | Санофи Пастер Байолоджикс Ко. | Рекомбинантный флавивирус и его применение |
BRPI0609949A2 (pt) | 2005-04-24 | 2010-05-11 | Acambis Inc | flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus |
WO2006134433A1 (fr) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Souche atténuée de dengue de sérotype 1 |
BRPI0504945B8 (pt) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
CN203286821U (zh) | 2013-05-03 | 2013-11-13 | 珠海格力电器股份有限公司 | 双级增焓空调系统 |
-
2003
- 2003-01-15 EP EP03748884A patent/EP1471873A4/fr not_active Withdrawn
- 2003-01-15 BR BR122018075729A patent/BR122018075729B8/pt not_active IP Right Cessation
- 2003-01-15 AU AU2003267937A patent/AU2003267937C1/en active Active
- 2003-01-15 KR KR1020047011000A patent/KR101074175B1/ko active IP Right Grant
- 2003-01-15 ES ES20159597T patent/ES2924640T3/es not_active Expired - Lifetime
- 2003-01-15 JP JP2004510692A patent/JP2005519639A/ja not_active Withdrawn
- 2003-01-15 MX MXPA04006870A patent/MXPA04006870A/es active IP Right Grant
- 2003-01-15 CA CA2473321A patent/CA2473321C/fr not_active Expired - Lifetime
- 2003-01-15 EP EP10013094A patent/EP2295023A1/fr not_active Withdrawn
- 2003-01-15 BR BR122018075730-2A patent/BR122018075730B1/pt not_active IP Right Cessation
- 2003-01-15 WO PCT/US2003/001214 patent/WO2003103571A2/fr active Application Filing
- 2003-01-15 CN CN201210162177.2A patent/CN103555669B/zh not_active Expired - Lifetime
- 2003-01-15 KR KR1020107028588A patent/KR101194818B1/ko active IP Right Grant
- 2003-01-15 BR BRPI0306905A patent/BRPI0306905B8/pt not_active IP Right Cessation
- 2003-01-15 US US10/345,036 patent/US7459160B2/en not_active Expired - Lifetime
- 2003-01-15 NZ NZ534159A patent/NZ534159A/en not_active IP Right Cessation
- 2003-01-15 EP EP20159597.2A patent/EP3679915B1/fr not_active Expired - Lifetime
-
2004
- 2004-07-13 IL IL163001A patent/IL163001A/en active IP Right Grant
-
2008
- 2008-12-01 US US12/325,864 patent/US20090191240A1/en not_active Abandoned
-
2010
- 2010-07-05 JP JP2010152899A patent/JP5554646B2/ja not_active Expired - Lifetime
-
2012
- 2012-11-05 US US13/668,819 patent/US8852914B2/en not_active Expired - Lifetime
- 2012-12-05 IL IL223457A patent/IL223457A/en active IP Right Grant
- 2012-12-05 IL IL223458A patent/IL223458A0/en unknown
-
2014
- 2014-10-06 US US14/507,319 patent/US10172929B2/en not_active Expired - Lifetime
-
2018
- 2018-11-26 US US16/199,831 patent/US20190192649A1/en not_active Abandoned
-
2023
- 2023-01-12 FR FR23C1005C patent/FR23C1005I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR23C1005I1 (fr) | Vaccins contre les flavivirus | |
MA28609B1 (fr) | Vaccins | |
IL177667A0 (en) | Flavivirus vaccines | |
MA28639B1 (fr) | Vaccins | |
EP1804831A4 (fr) | Vaccins à base de llo et de listéria | |
MA28885B1 (fr) | vaccins | |
IL173921A0 (en) | Vaccine | |
GB0329146D0 (en) | Vaccine | |
GB0212046D0 (en) | Vaccines | |
GB0411150D0 (en) | Vaccine | |
GB0323840D0 (en) | Vaccines | |
GB0305794D0 (en) | Vaccine | |
GB0328753D0 (en) | Hepatitis B vaccines | |
GB0330079D0 (en) | Vaccine | |
GB0321614D0 (en) | Vaccines | |
GB0305793D0 (en) | Vaccine | |
GB0304634D0 (en) | Vaccines | |
TWI350174B (en) | Adjuvanted bovine vaccines | |
GB0212036D0 (en) | Vaccines | |
GB0308691D0 (en) | Vaccine preparations | |
GB0406598D0 (en) | Vaccine | |
GB0330007D0 (en) | Vaccines | |
GB0300914D0 (en) | Vaccines | |
GB0304635D0 (en) | Vaccines | |
GB0304672D0 (en) | Vaccines |